Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASPIRE
NCT06931340Phase 3Recruiting
- Sponsor
- Cancer and Leukemia Group B
- Start
- Dec 2025
- Primary completion
- Nov 2031
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of docetaxel in prostate cancer (PCa), sponsored by Cancer and Leukemia Group B. Started Dec 2025; status: recruiting.
02
Drugs
docetaxel
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06931340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06931340.